Comparison of the effects of amitriptyline and paroxetine in the treatment of fibromyalgia syndrome

WOS: 000179727900007The aim of this study is to research the efficiency and the side effects of paroxetine, which is a selective serotonin re-uptake inhibitor (SSRI), and to compare it with amitriptyline, whose efficiency in fibromyalgia syndrome (FMS) is well known. The 40 FMS-diagnosed patients that were involved in the research were separated into two groups randomly. The patients within the first group were given paroxetine tablets (for the first weeks 20 mg/day, later 40 mg/day); those within the second group were given amitriptyline drage (for the first two weeks 10 mg/day, later 20 mg/day). The treatment continued for two months. All of the patients were evaluated by a physician, who was not aware of the therapy options, in the 2(nd), 4(th) and 8(th) weeks with regard to fatigue, morning stiffness, sleep disturbances, paraesthesia, headaches, tender point count and score, severity of global pain, Beck depression index, global efficiency and tolerance according to the patient and the physician's judgments. It is observed that paroxetine has shown good efficiency in treating the symptoms of FMS with the exception of fatigue (p < 0.5), but amitriptyline works better. The most important side effect of paroxetine is sexual dysfunction. Paroxetine therefore can be used as an alternative drug in FMS when the patients cannot use amitriptyline for any reason

Comparison of the effects of alfacalcidol-alendronate-calcium and vitamin D-alendronate-calcium treatments in postmenopausal osteoporosis

IOF World Congress on Osteoporosis -- MAY 14-18, 2004 -- Rio de Janeiro, BRAZILWOS: 000221453600361Int Ostoeporosis Fd

Translation and validation of the Turkish version of the arthritis impact measurement scales 2 in patients with knee osteoarthritis

PubMed ID: 15996073Objective. To translate and evaluate the validity, reliability, and acceptability of Arthritis Impact Measurement Scales 2 (AIMS2) in patients with knee osteoarthritis (OA). Methods. Turkish AIMS2 was developed using the "translation-backward translation" method and administered to 141 patients with symptomatic knee OA. Reliability was assessed by test-retest and internal consistency analyses. Construct validity was assessed by correlating the AIMS2 scales with Western Ontario and McMaster University Osteoarthritis Index (WOMAC), 100 mm visual analog scale (VAS) for pain, patient's and physician's global assessment, range of motion (ROM), and Kellgren-Lawrence grading system. Results. Test-retest reliability coefficients ranged from 0.75-0.98, and Cronbach's alpha coefficients from 0.72-0.90. Significant moderate to high correlations were obtained between AIMS2 scales (except social activities and support from family and friends scales) and most of the other clinical measurements. Conclusion. Turkish AIMS2 is a valid, reliable, and acceptable instrument in patients with symptomatic knee OA

Reliability, validity and sensitivity to change of Turkish versions of the neck disability index and the Northwick Park Neck Pain Questionnaire

Annual European Congress of Rheumatology -- JUN 08-11, 2005 -- Vienna, AUSTRIAWOS: 00022990910239